Quick Answer
ABEONA THERAPEUTICS INC. reported Total Revenue of $5.82 million for fiscal year 2025.
ABEONA THERAPEUTICS INC. — Key Financials by Year
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Total Revenue | $5.82M | — | $3.50M +147.5% |
$1.41M -52.9% |
$3.00M -70.0% |
$10.00M |
| Revenue (ASC 606) | $5.82M | — | $3.50M +147.5% |
$1.41M -52.9% |
$3.00M -70.0% |
$10.00M |
| Net Income | $71.18M +211.7% |
-$63.73M -17.6% |
-$54.19M -36.5% |
-$39.70M +53.3% |
-$84.94M -0.8% |
-$84.23M -10.4% |
| Diluted EPS | $1.01 +165.2% |
-$1.55 +38.7% |
-$2.53 +54.2% |
-$5.53 | — | — |
| Total Assets | $219.57M +101.6% |
$108.93M +70.2% |
$64.00M -0.3% |
$64.21M -19.3% |
$79.59M -47.4% |
$151.20M -32.3% |
| Cash and Equivalents | $78.44M +235.8% |
$23.36M +61.4% |
$14.47M +1.8% |
$14.22M -56.8% |
$32.94M +161.5% |
$12.60M -90.3% |
| Long-Term Debt | $7.81M -40.1% |
$13.04M | — | — | — | — |
| Stockholders Equity | $159.22M +261.6% |
$44.03M +197.0% |
$14.83M -44.6% |
$26.76M -36.8% |
$42.37M -58.7% |
$102.55M -42.5% |
| R&D Expense | $26.81M -22.0% |
$34.36M +10.5% |
$31.09M +7.3% |
$28.96M -25.2% |
$38.73M +28.5% |
$30.14M -37.9% |
| Operating Income | -$89.45M -39.3% |
-$64.21M -36.2% |
-$47.13M +7.4% |
-$50.91M +43.3% |
-$89.84M -10.3% |
-$81.42M -5.6% |
| Shares Outstanding | 55.04M +20.6% |
45.64M +72.1% |
26.52M +49.7% |
17.72M +200.9% |
5.89M -93.9% |
96.13M +15.0% |
Most Recent Quarter
| Metric | Quarter Ending | Value | YoY | QoQ |
|---|---|---|---|---|
| Total Revenue | June 30, 2025 | $400.0K | — | -88.6% |
| Revenue (ASC 606) | June 30, 2025 | $400.0K | — | -88.6% |
| Net Income | September 30, 2025 | -$5.16M | +82.9% | -104.7% |
| Diluted EPS | September 30, 2025 | -$0.10 | +84.1% | -105.8% |
| Total Assets | September 30, 2025 | $231.09M | +91.6% | -6.1% |
| Cash and Equivalents | September 30, 2025 | $82.88M | +427.1% | -49.3% |
| Long-Term Debt | September 30, 2025 | $10.86M | -23.5% | -22.4% |
| Stockholders Equity | September 30, 2025 | $171.23M | +274.1% | +4.7% |
| R&D Expense | September 30, 2025 | $4.22M | -52.8% | -29.1% |
| Operating Income | September 30, 2025 | -$24.02M | -56.5% | -5.4% |
| Shares Outstanding | September 30, 2025 | 52.40M | +20.7% | +2.2% |
- ABEONA THERAPEUTICS INC. reported Total Revenue of $5.82 million for fiscal year 2025.
- ABEONA THERAPEUTICS INC. showed an increase of +66.3% in Total Revenue compared to the prior fiscal year.
- ABEONA THERAPEUTICS INC. reported Revenue (ASC 606) of $5.82 million for fiscal year 2025.
- ABEONA THERAPEUTICS INC. showed an increase of +66.3% in Revenue (ASC 606) compared to the prior fiscal year.
- ABEONA THERAPEUTICS INC. reported Net Income of $71.18 million for fiscal year 2025.
- ABEONA THERAPEUTICS INC. showed an increase of +211.7% in Net Income compared to the prior fiscal year.
- ABEONA THERAPEUTICS INC. reported Diluted EPS of $1.01 per share for fiscal year 2025.
- ABEONA THERAPEUTICS INC. showed an increase of +165.2% in Diluted EPS compared to the prior fiscal year.
- ABEONA THERAPEUTICS INC. reported Total Assets of $219.57 million for fiscal year 2025.
- ABEONA THERAPEUTICS INC. showed an increase of +101.6% in Total Assets compared to the prior fiscal year.
- ABEONA THERAPEUTICS INC. reported Cash and Equivalents of $78.44 million for fiscal year 2025.
- ABEONA THERAPEUTICS INC. showed an increase of +235.8% in Cash and Equivalents compared to the prior fiscal year.
- ABEONA THERAPEUTICS INC. reported Long-Term Debt of $7.81 million for fiscal year 2025.
- ABEONA THERAPEUTICS INC. showed a decrease of -40.1% in Long-Term Debt compared to the prior fiscal year.
- ABEONA THERAPEUTICS INC. reported Stockholders Equity of $159.22 million for fiscal year 2025.
- ABEONA THERAPEUTICS INC. showed an increase of +261.6% in Stockholders Equity compared to the prior fiscal year.
- ABEONA THERAPEUTICS INC. reported R&D Expense of $26.81 million for fiscal year 2025.
- ABEONA THERAPEUTICS INC. showed a decrease of -22.0% in R&D Expense compared to the prior fiscal year.
- ABEONA THERAPEUTICS INC. reported Operating Income of -$89.45 million for fiscal year 2025.
- ABEONA THERAPEUTICS INC. showed a decrease of -39.3% in Operating Income compared to the prior fiscal year.
- ABEONA THERAPEUTICS INC. reported Shares Outstanding of 55.04 million shares for fiscal year 2025.
- ABEONA THERAPEUTICS INC. showed an increase of +20.6% in Shares Outstanding compared to the prior fiscal year.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: